Sponsors
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Blog
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?25 May 2011
White Papers
Focus Area: Lead Features
A Bright Outlook
Natalie Brandweiner talks to Lilly’s William Chin about personalized medicine, partnerships, and using the company’s PD2 initiative is generate new compounds.
Up Close and Personal
Reinventing big pharma’s corporate image has been pivotal in EMD Serono’s personalized approach. President and CEO Fereydoun Firouz tells NGP’s Natalie Brandweiner about the company’s drive to innovate, its community spirit, and its participation in the conversations around healthcare reform in the United States.
Golden Age of Discovery
Martin Mackay, Pfizer’s President of Global R&D, explains how in the age of tailored therapies, the end of diseases is in sight, and how the merger with Wyeth will set the company at the forefront of drug discovery.
The Small Company That Grew
Once a minor force in the world pharmaceutical market, Nycomed became a major player following its acquisition of Altana Pharma in 2006. CEO Håkan Björklund tells Marie Shields how the company is positioned to meet the challenges of its extraordinary growth.
Made to Measure
With pipelines running dry and fortunes flagging, the pharmaceutical industry is casting about for a savior. Could individually tailored treatments be the answer? By Marie Shields
Source: www.ngpharma.com© 2012 GDS Publishing Ltd. All rights reserved.